Krystal Biotech, Inc. Files Definitive Proxy Statement (DEF 14A)

TL;DR

<b>Krystal Biotech, Inc. has filed its Definitive Proxy Statement (DEF 14A) for the period ending April 4, 2024, detailing executive compensation and equity award information.</b>

AI Summary

Krystal Biotech, Inc. (KRYS) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. Krystal Biotech, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2024. The filing covers the period ending April 4, 2024. The company's principal executive offices are located at 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203. The SIC code for Krystal Biotech, Inc. is 2836, indicating Biological Products (No Diagnostic Substances). The filing includes information related to equity awards and their adjustments for the fiscal years 2020 through 2023.

Why It Matters

For investors and stakeholders tracking Krystal Biotech, Inc., this filing contains several important signals. This DEF 14A filing is crucial for shareholders as it outlines proposals to be voted on at the annual meeting, including the election of directors and executive compensation matters. Understanding the details of equity awards and their adjustments provides insight into the company's strategy for incentivizing key personnel and retaining talent, which can impact future performance.

Risk Assessment

Risk Level: — Krystal Biotech, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material financial information or significant operational changes.

Analyst Insight

Shareholders should review the proxy statement to understand executive compensation and vote on relevant proposals at the upcoming meeting.

Key Numbers

• 2024-04-04 — Filing Date (Date the DEF 14A was filed)
• 2024-04-04 — Period of Report (The period the filing is as of)
• 2836 — SIC Code (Standard Industrial Classification for Biological Products)

Key Players & Entities

• Krystal Biotech, Inc. (company) — Filer of the DEF 14A
• 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203 (location) — Company's business and mailing address

FAQ

Industry Context

Krystal Biotech operates in the biotechnology sector, focusing on the development and commercialization of novel therapies.

Regulatory Implications

As a publicly traded company, Krystal Biotech is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.

What Investors Should Do

1. Review the detailed breakdown of executive compensation and equity awards.
2. Understand the proposals to be voted on at the shareholder meeting.
3. Assess the company's governance practices as outlined in the filing.

Key Dates

• 2024-04-04: Filing of DEF 14A — Indicates the company is providing formal disclosure regarding shareholder matters and executive compensation.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document. No prior filing of this specific type is referenced in the provided text for comparison.

Key Financial Figures

• $0.00001 — f record of our common stock, par value $0.00001 per share (our " Common Stock "), at th

Filing Documents

• krys-20240403.htm (DEF 14A) — 871KB
• krys-20240403_g1.jpg (GRAPHIC) — 52KB
• krys-20240403_g2.jpg (GRAPHIC) — 182KB
• krys-20240403_g3.jpg (GRAPHIC) — 125KB
• krys-20240403_g4.jpg (GRAPHIC) — 429KB
• krys-20240403_g5.jpg (GRAPHIC) — 182KB
• 0001711279-24-000013.txt (&nbsp;) — 3755KB
• krys-20240403.xsd (EX-101.SCH) — 4KB
• krys-20240403_def.xml (EX-101.DEF) — 6KB
• krys-20240403_lab.xml (EX-101.LAB) — 8KB
• krys-20240403_pre.xml (EX-101.PRE) — 5KB
• krys-20240403_htm.xml (XML) — 178KB

From the Filing

krys-20240403 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 KRYSTAL BIOTECH, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. April 4, 2024 Dear Fellow Stockholders: You are cordially invited to attend the 2024 annual meeting of stockholders (the " Annual Meeting ") of Krystal Biotech, Inc., which will be held virtually at www.virtualshareholdermeeting.com/KRYS2024, on May 17, 2024, at 4:00 p.m. Eastern Time. The matters expected to be acted upon at the Annual Meeting are described in detail in the accompanying Notice of Annual Meeting of Stockholders and Proxy Statement. In accordance with U.S. Securities and Exchange Commission "notice and access" rules, we are using the Internet as our primary means of furnishing proxy materials to our stockholders. Because we are using the Internet, most stockholders will not receive paper copies of our proxy materials. We will instead send our stockholders a notice with instructions for accessing the proxy materials and voting via the Internet. This notice also provides information on how our stockholders may obtain paper copies of our proxy materials if they so choose. We believe the use of the Internet makes the proxy distribution process more efficient and less costly and helps in conserving natural resources. The Proxy Statement, the accompanying form of proxy card, the Notice of Annual Meeting of Stockholders and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, are available at www.proxyvote.com and may also be accessed through our website at www.krystalbio.com under the "SEC Filings" section of the "Investors" page. If you would like to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a copy. Your vote is important. Please cast your vote as soon as possible over the Internet, by telephone, or by completing and returning the proxy card to ensure that your shares are represented. Your vote by proxy will ensure your representation at the Annual Meeting regardless of whether or not you attend the Annual Meeting. Casting your vote by proxy does not deprive you of your right to attend the Annual Meeting and vote your shares. On behalf of our Board of Directors and our employees, we thank you for your continued interest in and support of our company. We look forward to your attendance at the Annual Meeting on May 17, 2024. Sincerely, /s/ Krish S. Krishnan Krish S. Krishnan Chairman and Chief Executive Officer KRYSTAL BIOTECH, INC. 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held on May 17, 2024 NOTICE IS HEREBY GIVEN that the 2024 annual meeting of stockholders (the " Annual Meeting ") of Krystal Biotech, Inc. will be held virtually at www.virtualshareholdermeeting.com/KRYS2024, on May 17, 2024, at 4:00 p.m. Eastern Time, for the following purposes: (1) to elect the three Class I director nominees named in the Proxy Statement; (2) to ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024; (3) to consider and act upon a non-binding, advisory vote on the compensation of our named executive officers; and (4) to transact such other business as may properly come before the Annual Meeting or any adjournment(s) or postponement(s) of the Annual Meeting. The Proxy Statement accompanying this notice describes each of these items of business in detail. The Board of Directors has fixed the close of business on March 25, 2024, as the record date for the determination of stockholders entitled to notice of and to vote at the Annual Meeting and any adjournments or postponements of the Annual Meeting (the " Record Date "). Accordingly, only stockholders of record at the close of business on March 25, 2024, are entitled to notice of, and to vote at, the Annual Meeting and any adjournments or postponements of the Annual Meeting. On or about April 4, 2024, we expect to mail to our stockholders entitled to notice of and to vote at the Annual Meeting a Notice of Internet Availability of Proxy Materials (the " Notice ") containing instructions on how to access our Proxy Statement and

View Full Filing

View this DEF 14A filing on SEC EDGAR